Core Viewpoint - In 2025, Laimei Pharmaceutical achieved significant milestones in innovation and product development, enhancing its position in the pharmaceutical industry through successful clinical trials and recognition for its innovative products. Group 1: Innovation and R&D - The clinical trial for the innovative anti-cancer drug "Nano Carbon Iron Suspension Injection" was approved, allowing it to be tested in solid tumor patients [2][4] - The drug is based on the existing Nano Carbon Suspension Injection and utilizes Fe2+ as an active anti-cancer component [4] - Laimei's generic drug "Mabalaoshuwei Tablets" received ethical approval and entered the bioequivalence trial phase [5] - "Nano Carbon Suspension Injection" was selected as one of the first batch of iconic products in future industries by the Chongqing Municipal Economic and Information Technology Commission [8] - "Injection Esomeprazole Sodium" was recognized as a major industrial technology innovation product for 2024 by the Chongqing Municipal Economic and Information Technology Commission [10] Group 2: Market Expansion and Product Selection - Laimei's product "Nicorandil Tablets" was selected in the 11th batch of national drug centralized procurement, marking its entry into the mainstream medical market [12][13] - Multiple products from Laimei were selected in the Guangdong Alliance centralized procurement, enhancing accessibility to essential medications [15][16][18] Group 3: Brand Recognition and Awards - Laimei was included in the "Top 50 Comprehensive Strength List" of the 2024 China Innovative Drug Value Ranking, reflecting its commitment to innovation [22] - The company received the "Golden Information Disclosure Award" for the second consecutive year, recognizing its excellence in information disclosure and compliance [24] - Laimei was awarded the title of "Leading Enterprise in Manufacturing Innovation" by the Chongqing Economic Development Zone [26] - The company was recognized as a "Pilot Enterprise for Strong Party Building" in the Nanan District, highlighting its commitment to governance and community engagement [31]
稳进·突破·引领——莱美药业2025年度回顾